加拿大保险公司对药物遗传测试的覆盖范围
Ruby Brubaker-Plitt1, Chad A Bousman2,3,4
1College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.
Pharmacogenetics and genomics
|November 3, 2025
概括
加拿大药物遗传学 (PGx) 测试的访问受到保险覆盖的限制. 这次审查发现保险公司政策存在显著差异,影响了个人化医疗的公平获取,并突出了对标准化PGx测试覆盖的需要.
科学领域:
- 药物基因组学 药物基因组学
- 医疗保险政策 医疗保险政策
- 临床遗传学 临床遗传学
背景情况:
- 在加拿大,对药物遗传学 (PGx) 测试的访问受到限制,通常是由于研究环境之外的高成本.
- 加拿大保险公司开始覆盖PGx测试,但该保险的具体细节尚未明确.
研究的目的:
- 系统地审查加拿大保险公司公开提供的PGx测试保险政策.
- 评估资格标准,附属实验室和保险公司提供的PGx测试面板的临床实用性.
主要方法:
- 对十家加拿大保险公司的公开可访问的PGx保险政策进行系统审查.
- 分析政策细节,包括资格要求,实验室隶属以及PGx小组的范围.
主要成果:
- 六家保险公司提供部分退款/折扣,四家有特定的资格标准 (例如,残疾假,医生诊断).
- 资格要求高度变化,与保险公司关联的四个商业实验室在可采取行动的基因/药物测试数量方面存在差异.
- 保险公司的政策和实验室测试的全面性存在实质性的异质性,可能导致在获得和护理质量方面的不平等.
结论:
- 对于PGx测试的保险覆盖范围的变化可能会影响临床医生的建议和患者获得个性化治疗的机会.
- 加拿大急需制定标准化的PGx测试覆盖政策和协调的测试小组.
- 保险公司,研究人员和临床医生之间的合作对于开发加拿大特定证据至关重要,以指导公平有效的PGx实施.
相关概念视频
01:24Dosage Regimen: Individualization
161
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
161
01:29Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
144
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
144
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
01:16Therapeutic Drug Monitoring: Overview and Classification
293
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
293
01:12Analysis of Population Pharmacokinetic Data
669
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
669